## Your Anoro Ellipta inhaler



When you take your Anoro Ellipta inhaler out of the sealed tray, it will be in the 'closed' position. Don't open it until you're ready to inhale a dose of medicine.

When you first use your Anoro Ellipta inhaler, you do not need to check that it's working properly, and you do not need to prepare it for use in any special way. Sliding open the cover automatically prepares a dose.

The dose counter lets you know how many doses you have left in the inhaler. When fewer than 10 doses are left, half the dose counter shows red, so get in touch with your doctor about another prescription before you run out of medicine.

After you have used the last dose, half the dose counter shows red and the number 0 is displayed. Your inhaler is now empty.

KEEP YOUR MEDICINE OUT OF THE SIGHT AND REACH OF CHILDREN.

### Take the COPD assessment test

to measure the impact of COPD on your everyday life. Discuss the results of the test with your healthcare professional to better manage your COPD.



## ANORO ELLIPTA umeclidinium/vilanterol

#### References:

- 1. Anoro Ellipta Consumer Medicine Information, GSK New Zealand.
- Anoro Ellipta Data Sheet, GSK New Zealand. Can be accessed at medsafe.qovt.nz
- 3. Donohue JF et al. Resp Med. 2013; 107:1538-46.

Anoro Ellipta is contraindicated in patients with lactose or milk-protein allergy or who have demonstrated hypersensitivity to umeclidinium bromide, vilanterol trifenatate or any of the excipients.

Anoro Ellipta (umeclidinium [asbromide] 62.5 mcg, vilanterol [as trifenatate] 25 mcg inhaler) is a Prescription Medicine. Anoro Ellipta is used for long-term regular treatment to relieve symptoms in adults with Chronic Obstructive Pulmonary Disease (COPD). Anoro Ellipta is a fully funded medicine if you are diagnosed with COPD-restrictions apply. Use strictly as directed. Do not take Anoro Ellipta to treat asthma or to relieve acute symptoms. Always carry your reliever inhaler. Tell your doctor: if you have severe milk-protein allergy, or you have demonstrated hypersensitivity to either umeclidinium, vilanterol trifenatate or any of the excipients in Anoro Ellipta; or if you are taking any other medicines including any that you get without a prescription from your pharmacy, supermarket or health food shop; if you have asthma; if you have heart problems or high blood pressure; if you have an enlarged prostate, difficulty passing urine, or a blockage in your bladder; narrow-angle glaucoma; or if you are pregnant or plan to become pregnant or are breast-feeding.

**Side Effects:** Sore throat with or without a runny nose, cough, painful and frequent urination, infection of the upper airways, pain of the sinuses, faster heartbeat, feeling of pressure or pain in the cheeks and forehead. *Anoro Ellipta* has risks and benefits. **If symptoms continue or you have side effects, see your doctor, pharmacist or health care professional.** 

For more information see the *Anoro Ellipta* Consumer Medicine Information at <a href="https://www.medsafe.govt.nz">www.medsafe.govt.nz</a>. Ask your doctor if *Anoro Ellipta* is right for you. Normal doctor's charges apply.

Trade marks are owned by or licensed to the GSK group of companies. ©2023 GSK group of companies or its licensor. Anoro Ellipta was developed in collaboration with Innoviva Inc. Marketed by GlaxoSmithKline NZ Limited, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.


Date of Approval: 09 2023 Date of expiry: 09 2025
TAPS NP18220 PM-NZ-UCV-PINF-220002 GSK1024

# Is your COPD holding you back?



For more information about ANORO ELLIPTA

visit anoroellipta.co.nz



## What is Anoro Ellipta?

Anoro Ellipta is a long-term treatment for people with Chronic Obstructive Pulmonary Disorder (COPD), sometimes called emphysema or chronic bronchitis.

It is used as a once daily treatment for the relief of COPD symptoms, such as breathlessness.<sup>1,2</sup>

Anoro Ellipta is particularly helpful for people with COPD who run out of breath easily or become puffed while doing everyday activities.<sup>1</sup>

Anoro is a combination of two medicines called umeclidinium and vilanterol, and Ellipta is the device that allows both medicines to be inhaled at the same time.<sup>1,2</sup>

Anoro Ellipta should not be used to relieve sudden breathing problems and won't replace a rescue inhaler.<sup>1</sup>

### How does Anoro Ellipta help you breathe better?

The medicines in Anoro Ellipta work together to help open the airways and make it easier for air to get in and out of the lungs.<sup>1</sup>

This helps control the breathing difficulties and breathlessness caused by COPD and minimises the effects of the disease on your everyday life.<sup>3</sup>

#### When should I take it?

You can take Anoro Ellipta at any time but make sure it's always at the same time every day. This will help you keep free of symptoms for 24 hours at a time.

If you miss a dose, take it as soon as you remember but take no more than one inhalation per day. After that, go back to taking your dose at the usual time.<sup>1</sup>

#### Possible side effects

Like all medicines, Anoro Ellipta can cause side effects, although not everybody gets them. Common side effects, which may affect up to one in ten people, include sore throat with or without runny nose, cough, constipation, dry mouth, painful and frequent urination (which may be signs of a urinary tract infection), feeling of pressure or pain in the cheeks and forehead (which may be signs of inflammation of the sinuses called sinusitis), pain and irritation in the back of the mouth and throat, and infection of the upper airways.<sup>1</sup>

Note that this is not a complete list of side effects, please refer to the Consumer Medicine Information or more details (available from www.medsafe.govt.nz).

### How do you use Anoro Ellipta?

Follow these three very simple steps or simply scan the QR code with your smartphone camera to watch a video demonstration to help you breathe better now with Anoro Ellipta.



This is a 3rd party website and is not owned or monitored by GSK

One



Two



**Three** 







